Almac and TTP combine Flurescence Lifetime Technology

By Dan Stanton

- Last updated on GMT

Related tags Drug discovery

Almac harness new Ameon reader for FLT
Almac harness new Ameon reader for FLT
Almac says that a cost-cutting plate reader technology developed by TTP Labtech is an ideal addition to its drug discovery offering.

The technology – The Ameon reader – will be used to analyse the results of discovery assays conducted using Almac’s Flexlyte fluorescence lifetime technology (FLT) platform.

Senior R&D director Graham Cotton told Outsourcing-pharma.com “the combination of the Flexyte assay technology with the Ameon plate-reader provides a robust, cost-effective platform for screening against the major therapeutic target classes that minimises compound interference and is suitable for HTS and profiling applications and enhancing productivity​.”

He added that the reader offers a “real-time decay curve analysis, [which] provides a revolutionary combination of speed, precision, and data quality for FLT assays that can be readily integrated into HTS (high-throughput screening) workflows.”

Further details of the alliance including financial and exclusivity implications were not disclosed.

Flexlyte

Developed by Almac with Edinburgh Instruments​, the Flexylyte system uses the principle of “fluorescence lifetime” (the length of time a molecule remains excited) to measure activity of protein kinase targets when they enter drug candidates. The platform is based on a range of long half-life dyes derived 9-aminoacridine (9AA) as the fluorescent reporter that is ideally suited for assay applications.

This has allowed configuration “for a broad panel of drug targets including protein kinases, proteases, DUB, protein-protein interactions and an increasing number of epigenetic targets​,”  according to Cotton.

Further News

TTP Labtech announces a new, faster imager for multiplex assays to be launched next week.

The acumen hci (high content imaging) system offers unparalleled speeds during HTS without compromising content and will complement traditional imaging systems, according to TTP’s product manager Paul Wylie.

“The acumen hci can be used for cell based assays including compound screening and RNAi studies to provide images of “hit” wells at the highest throughput. These specific hits can then be further analysed for hit confirmation at slower speeds and higher magnification if required.”

Related topics Preclinical Research Preclinical

Related news

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars